THE WOODLANDS, Texas, Sept. 8, 2015 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from its Phase 2 clinical study of sotagliflozin in type 1 diabetes will be presented in oral and poster presentations at the European Association for the Study of Diabetes, which will be held September 1418 in Stockholm, Sweden.
Currently in Phase 3 clinical development for the treatment of type 1 diabetes, sotagliflozin is the first investigational therapy to target both SGLT1 and SGLT2, key proteins that transport glucose in the body.
The oral presentation, entitled “Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improves glycaemic control in type 1 diabetes mellitus in a randomised, placebo-controlled, double-blind study,” will be presented at 3:45 p.m., September 17, by John B. Buse, M.D., Ph.D., Professor of Medicine and Chief of the Division of Endocrinology at the University of North Carolina, Chapel Hill.
The poster, entitled “Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces glucose variability in type 1 diabetes mellitus in a randomised, placebo-controlled, double-blind study,” will be presented at 2:15 p.m., September 17, by Paul Strumph, M.D., Lexicon’s Vice President of Clinical Development and the development lead for sotagliflozin.
About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is a first-in-class dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin has been shown in a Phase 2 study to improve glycemic control in people with type 1 diabetes while reducing their need for mealtime insulin. Lexicon is conducting Phase 3 clinical trials of sotagliflozin and retains full worldwide rights to market the compound.
About Lexicon
Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science, based on Nobel Prize-winning technology, to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000 program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism. For additional information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s clinical development of sotagliflozin (LX4211) and the results of and projected timing of clinical trials and the potential therapeutic and commercial potential of sotagliflozin. In addition, this press release also contains forward-looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the risk that clinical studies of sotagliflozin may be halted, delayed or otherwise not demonstrate safety or efficacy, the risk that Lexicon may be unable to file for regulatory approval of sotagliflozin with the FDA and other regulatory authorities in accordance with its currently anticipated timelines, the risk that the FDA and other regulatory authorities may not grant regulatory approval of sotagliflozin in accordance with Lexicon’s currently anticipated timelines or at all, and the risk that such regulatory approvals, if granted, may have significant limitations on the approved use of sotagliflozin. As a result, sotagliflozin may never be successfully commercialized. Other risks include Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other potential drug candidates, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lexicon-announces-sotagliflozin-data-to-be-presented-at-european-association-for-the-study-of-diabetes-300138534.html
SOURCE Lexicon Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
